Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 11NIH 4NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Advanced Rare Tumours 1

Interventions

Specimen Handling 68Magnetic Resonance Spectroscopy 53Cyclophosphamide 45Vincristine 38Radiotherapy 31Radiation 31Cisplatin 31Carboplatin 30Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Platinum 16Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × temsirolimus × 1 year × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

NCT03297606 2026-03-27

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting
720 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡